Calculus participates in £6m Collagen injection

Part of the capital commitment will be used to acquire Southern Light Biomaterials, a New Zealand-based developer and manufacturer of medical grade collagen components. Southern Light was founded in 2003 and has its largest customer base in South Korea.

Remaining capital will support the development of Collagen's operational activities, and help to boost its sales and marketing efforts.

Following the acquisition, Collagen has relisted on the AIM segment of the London Stock Exchange as an enlarged business with a market-cap of £5.82m. The listed business aims to achieve a £100m market-cap by 2020.

Company
Collagen provides medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics.

The firm initially listed on the LSE in January 2014 when Collbio bought the assets of US-based Collagen Solutions and underwent a reverse takeover, becoming Collagen Solutions.

The company is headquartered in Glasgow.

People
Rick Jones is investment director at Calculus. Stewart White is chief executive of Collagen.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• PIPEs
• Portfolio management
• United Kingdom